Abstracts Archive - Page 750 of 2607 - ACR Meeting Abstracts

Abstract Number: 0673 • ACR Convergence 2021
The Impact of Allopurinol on Blood Pressure and Renal Outcome in Gout Patients: A Retrospective Study
Aniqa Faraz¹, Sabeeh Islam², Joseph Grisanti³ and Shumaila Iqbal⁴, ¹University at Buffalo-CHS Sisters of Charity, Grand Island, NY, ²Brigham and Women's Hospital Cardiology, Boston, MA, ³Buffalo Rheumatology & Medicine, Orchard Park, NY, ⁴University of Cincinnati, Cincinnati, OH
Background/Purpose: The relationship between change in serum uric acid level and progression of chronic kidney disease and hypertension is still conflicting. In this study, we…
Abstract Number: 0674 • ACR Convergence 2021
A Behavioral Intervention to Improve Gout Outcomes in African Americans with Gout: A 12-month Multicenter, Randomized Controlled Trial
Jasvinder Singh¹, Kenneth Saag¹, Joshua Baker², Amy Joseph³, Seth Eisen⁴ and Terence Shaneyfelt¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Pennsylvania, Philadelphia, PA, ³Washington University / St. Louis VA, St Louis, MO, ⁴Washington University School of Medicine, St Louis, MO
Background/Purpose: Gout outcomes and severity are worst in African Americans compared to Caucasians with gout. Racial Disparities in gout are well-described. Few or no data…
Abstract Number: 0675 • ACR Convergence 2021
Urate-lowering Therapy for Prevention of Gout: Prespecified Analyses from the CKD-FIX Trial
Anushree Tiku¹, Neil Boudville², Fiona Brown³, Alan Cass⁴, Phiilip Clarke⁵, Richard Day⁶, Janak de Zoysa⁷, Bettina Douglas⁸, Randall Faull⁹, David Harris¹⁰, Carmel Hawley¹¹, Graham Jones⁶, John Kanellis³, Elaine Pascoe¹¹, Suetonia Palmer¹², Vlado Perkovic¹³, Gopala Rangan¹⁰, Donna Reidlinger¹¹, Laura Robison¹¹, Robert Walker¹⁴, Giles Walters¹⁵, David Johnson¹¹, Sunil Badve¹³ and Nicola Dalbeth⁷, ¹The George Institute of Australia, Sydney, Australia, ²University of Western Australia, Perth, Australia, ³Monash University, Melbourne, Australia, ⁴Menzies School of Health Research, Darwin, Australia, ⁵University of Oxford, Oxford, United Kingdom, ⁶University of New South Wales, Sydney, Australia, ⁷University of Auckland, Auckland, New Zealand, ⁸Princess Alexandra Hospital, Brisbane, Australia, ⁹University of Adelaide, Adelaide, Australia, ¹⁰University of Sydney, Sydney, Australia, ¹¹University of Queensland, Brisbane, Australia, ¹²University of Otago, Christchurch, New Zealand, ¹³The George Institute for Global Health, Sydney, Australia, ¹⁴University of Otago, Dunedin, New Zealand, ¹⁵The Canberra Hospital, Canberra, Australia
Background/Purpose: The CKD-FIX randomized controlled trial showed that allopurinol did not slow decline of estimated glomerular filtration rate (eGFR) over 104 weeks in patients with…
Abstract Number: 0676 • ACR Convergence 2021
Development, Refinement, and Validation of an Emergency Department Gout Flare Electronic Medical Record Alert
Lesley Jackson¹, Narender Annapureddy², Kenneth Saag¹, James Booth³, Giovanna Rosas¹, Jeffrey Foster¹, Amy Mudano¹, Dongmei Sun⁴, John Osborne¹, Tim Bongartz⁵, Erik Hess⁵, Colleen Lawrence⁶, Leah Dunkel⁶ and Maria I. Danila¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Vanderbilt University Medical Center, Nashville, TN, ³Department of Emergency Medicine, University of Alabama School of Medicine, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁵Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville, TN, ⁶Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Patients with acute gout are frequently treated in emergency departments (ED) and represent a typically underserved and understudied population. A key limitation of conducting…
Abstract Number: 0677 • ACR Convergence 2021
Pro-Inflammatory Diet and Increased Risk of Incident Female Gout: 30-Year Prospective Cohort Study of >170,000 Pre- and Post-Menopausal US Women
Natalie McCormick¹, Chio Yokose², Na Lu³, Amit Joshi¹ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital, Lexington, MA
Background/Purpose: Globally, the prevalence of gout is rising in females more than males,1 but data on modifiable risk factors for female gout are scarce. Emerging…
Abstract Number: 0678 • ACR Convergence 2021
Is There a Difference in Self-reported Flare Frequency Between Men and Women?
Naomi Schlesinger¹, Nicholas A Sumpter², Nicola Dalbeth³, Lisa Stamp⁴ and Tony Merriman⁵, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²University of Otago, Dunedin, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴University of Otago, Christchurch, Christchurch, New Zealand, ⁵University of Alabama at Birmingham, Dunedin, New Zealand
Background/Purpose: There is increasing recognition of gout among women. The postmenopausal rise in serum urate levels in women increases the risk for the development of…
Abstract Number: 0679 • ACR Convergence 2021
Cardiovascular Risk Associated with Treatment of Allopurinol and Benzbromarone in Patients with Gout
Yeonghee Eun, Seonyoung Kang, Seulkee Lee, Hyungjin Kim, Jaejoon Lee, Eun-Mi Koh and Hoon-Suk Cha, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Background/Purpose: Previous studies have shown that cardiovascular risk is increased in patients with gout. There are many studies on the effect of uric acid lowering…
Abstract Number: 0680 • ACR Convergence 2021
Gout Stigma: Investigating the Existence of Gout Stigma and Its Impact on Patient Perceptions and Treatment Decisions
N Lawrence Edwards¹, Brian LaMoreaux², Joseph Vitriol³ and Adam Magerman³, ¹University of Florida College of Medicine, Gainesville, FL, ²Horizon Therapeutics plc, Deerfield, IL, ³Horizon Therapeutics, Deerfield, IL
Background/Purpose: Pegloticase is FDA-approved for uncontrolled gout and effectively lowers uric acid levels by conversion of circulating uric acid to allantoin, which is readily removed…
Abstract Number: 0681 • ACR Convergence 2021
Assessing Patterns of Inpatient Gout Management: Pathway for Optimal Patient Treatment Outcomes
Evan Dombrosky¹, Yashswee KC², Joshua Gavin³, Youssef Roman³ and Nehal Shah³, ¹Virginia Commonwealth University Health System, Glen Allen, VA, ²Loyola University, Oak Park, IL, ³Virginia Commonwealth University Health System, Richmond, VA
Background/Purpose: Gout is the most common inflammatory arthropathy worldwide. Despite having evidence-based guidelines, inconsistent management approaches remain a significant barrier to adequate treatment and prevention.…
Abstract Number: 0682 • ACR Convergence 2021
Gout Management and Outcomes During the COVID-19 Pandemic in Late 2020-2021: A Cross-sectional Internet Survey
Jasvinder Singh¹ and N Lawrence Edwards², ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Florida College of Medicine, Gainesville, FL
Background/Purpose: To assess gout management during the COVID-19 pandemic since September 2020.Methods: We assessed urate-lowering therapy (ULT) use, healthcare utilization, gout-specific health-related quality of life…
Abstract Number: 0683 • ACR Convergence 2021
Predictors of Rapidly Progressive Interstitial Lung Disease and Mortality in Patients with Autoantibodies Against Melanoma Differentiation-Associated Protein 5 Dermatomyositis
Jacqueline So¹, Lai-Shan Tam², Priscilla Wong¹, Lydia Ho-Pui Tam¹, Tsz On Lam¹, Chi Chiu Mok³, Chi Hung To⁴, Yuen Kwan Chung⁴, Victor Tak Lung Wong⁵, Tsz Yuen Wu⁶, Roy Ho⁷, Wai Ling Li⁸, Chi Ho⁹ and Ho So¹⁰, ¹Prince of Wales Hospital, Hong Kong, Hong Kong, ²Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic), ³Tuen Mun Hospital, Hong Kong, China, ⁴Pok Oi Hospital, Hong Kong, Hong Kong, ⁵Kwong Wah Hospital, Hong Kong, Hong Kong, ⁶Princess Margaret Hospital, Hong Kong, Hong Kong, ⁷Queen Elizabeth Hospital, Hong Kong, Hong Kong, ⁸Queen Mary Hospital, Hong Kong, Hong Kong, ⁹Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong, ¹⁰CUHK, Hong Kong, China
Background/Purpose: Anti-melanoma differentiation-associated protein 5 (MDA5) positive dermatomyositis (DM) is associated with rapidly progressive interstitial lung disease (RP-ILD) and high mortality. This multi-centre retrospective study…
Abstract Number: 0684 • ACR Convergence 2021
Extended Report: Successful Treatment anti-MDA5 Antibody-positive Interstitial Lung Disease with Plasma Exchange Therapy
Yoshiyuki Abe¹, Masahiro Kogami², Makio Kusaoi², Kurisu Tada³, Ken yamaji⁴ and Naoto Tamura³, ¹Juntendo University School of Medicine, Tokyo, Japan, ²Juntendo University, Tokyo, Japan, ³Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan, ⁴Juntendo University School of Medicine Internal Medicine and Rheumatology, Tokyo, Japan
Background/Purpose: This study was extended report from our previous study that “Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy” (Rheumatology…
Abstract Number: 0685 • ACR Convergence 2021
Adipokines and Loss of Lean Mass Among Patients with Rheumatoid Arthritis
Joshua Baker¹, Jon Giles², Patrick Gould¹ and Patricia Katz³, ¹University of Pennsylvania, Philadelphia, PA, ²Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, ³University of California San Francisco, San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) is associated with loss of muscle mass and quality that can have significant impacts on physical functioning and quality of life.…
Abstract Number: 0686 • ACR Convergence 2021
Is It Useful to Assess Muscle Involvement with Positron Emission Tomography in Patients with Idiopathic Inflammatory Myositis? A Case-Control Study
Murat Bektaş¹, Emine Göknur Işık², Fatih Kemik³, Emin Oğuz⁴, Anna ABBASGHOLI ZADEH⁵, Burak Ince⁶, Zeynep Gözde Özkan⁷, Yasemin Yalcinkaya⁸, Bahar Esen⁸, Ahmet Gül⁹ and Murat İnanç⁴, ¹Istanbul Faculty of Medicine, Istanbul, Turkey, ²Istanbul University, Istanbul Faculty of Medicine, Department of Nuclear Medicine, İstanbul, Turkey, ³Istanbul Faculty of Medicine, Istanbul University, Department of Internal Medicine, İstanbul, Turkey, ⁴Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, ⁵Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, İstanbul, Turkey, ⁶Istanbul Faculty of Medicine, Istanbul University, Division of Rheumatology, İstanbul, Turkey, ⁷Istanbul Faculty of Medicine, Department of Nuclear Medicine, Istanbul, Turkey, ⁸Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ⁹Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey
Background/Purpose: Multiple diagnostic methods have been used to investigate muscle involvement in patients with idiopathic inflammatory myositis (IIM) such as electromyography (EMG) and muscle MRI.…
Abstract Number: 0687 • ACR Convergence 2021
Clinical Features and Prognosis of a Large North American Cohort of Adult MDA5+ Dermatomyositis
Christopher Mecoli¹, Eleni Tiniakou², William Kelly², Jemima Albayda², Julie Paik², Brittany Adler², Andrew Mammen³, Cheng Ting Lin¹, Sonye Danoff⁴, Livia Casciola-Rosen⁵ and Lisa Christopher-Stine², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³National Institutes of Health, Bethesda, MD, ⁴Johns Hopkins Medicine, Baltimore, MD, ⁵Johns Hopkins, Baltimore, MD
Background/Purpose: We describe a single-center North American adult cohort of MDA5-positive DM, with emphasis on the subgroup of patients that experience drug-free long-term remission. Methods:…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].